Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204523 | 0.78 | TNKS (0.54) | CYP19A1RAB9ANPC1MAOBALDH1A1 | |
| SCHEMBL4951498 | 0.78 | GLA (0.62) | RAB9ANPC1MAPTMAOBALDH1A1 | |
| Hydrochloric Acid SCHEMBL16826561 | 0.77 | GLA (0.60) | RAB9ANPC1MAPTMAOBALDH1A1 | |
| SCHEMBL29846430 | 0.75 | F2RL3 (0.40) | RAB9AMAPTGRM4PDPK1KDM4E | |
| SCHEMBL13801141 | 0.74 | MAPT (0.51) | CYP19A1RAB9ANPC1MAPTADRA2A | |
| SCHEMBL30036439 | 0.73 | MAOB (0.63) | RAB9ANPC1MAPTADRA2AGRM4 | |
| SCHEMBL103158 | 0.73 | MAOB (0.63) | RAB9ANPC1MAPTADRA2AGRM4 | |
| SCHEMBL17687570 | 0.73 | CYP19A1 (0.64) | CYP19A1RAB9ANPC1MAPTADRA2A | |
| SCHEMBL14936927 | 0.72 | MAPT (0.62) | CYP19A1RAB9ANPC1MAPTADRA2A | |
| SCHEMBL25441822 | 0.71 | ADORA2A (0.35) | CYP19A1RAB9ANPC1MAPTPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8325265-A | — | — | None | — | — | JP | disclosed |
| JP-10316678-A | — | — | None | — | — | JP | disclosed |
| JP-5202040-A | — | — | None | — | — | JP | disclosed |
| US-20170014384-A1 | METHOD FOR INHIBITING TUMOR METASTASIS | INFLAMMATION RES CENTER COMPANY LTD (JP) | 2017-01-19 | — | — | US | disclosed |
| CN-102847155-B | Method for inhibiting tumor metastasis | INFLAMMATION RES CT COMPANY LTD | 2014-04-16 | — | — | CN | disclosed |
| CN-101022796-B | Method for inhibiting tumor metastasis | INFLAMMATION RES CT COMPANY LTD | 2013-02-27 | — | — | CN | disclosed |
| CN-102847155-A | Method for inhibiting tumor metastasis | INFLAMMATION RES CT COMPANY LTD | 2013-01-02 | — | — | CN | disclosed |
| EP-1997491-B1 | Method for inhibiting tumor metastasis | INFLAMMATION RES CT COMPANY LT (JP) | 2010-09-22 | — | — | EP | disclosed |
| EP-1997491-A1 | Method for inhibiting tumor metastasis | Inflammation Research Center Company Ltd. (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20080206203-A1 | Administering leukotriene antagonist such as pranlukast | INFLAMMATION RESEARCH CENTER COMPANY LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-5296495-A | Antiallergens, antiinflammatory | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| JP-H05202040-A | THIAZOLYLBENZOFURAN DERIVATIVE | FUJISAWA PHARMACEUT CO LTD | 1993-08-10 | — | — | JP | disclosed |
| CN-1074444-A | New thiazolyl benzofuran derivative, its preparation method and contain the pharmaceutical composition of this derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-07-21 | — | — | CN | disclosed |
| CN-1074444-A | New thiazolyl benzofuran derivative, its preparation method and contain the pharmaceutical composition of this derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-07-21 | — | — | CN | disclosed |
| CN-1074444-A | New thiazolyl benzofuran derivative, its preparation method and contain the pharmaceutical composition of this derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-07-21 | — | — | CN | disclosed |
| CN-1070910-A | New thiazolyl benzofuran derivative, its preparation method and contain the pharmaceutical composition of this derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-04-14 | — | — | CN | disclosed |
| CN-1070910-A | New thiazolyl benzofuran derivative, its preparation method and contain the pharmaceutical composition of this derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-04-14 | — | — | CN | disclosed |
| CN-1070910-A | New thiazolyl benzofuran derivative, its preparation method and contain the pharmaceutical composition of this derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-04-14 | — | — | CN | disclosed |
| EP-0528337-A1 | New thiazolylbenzofuran derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| EP-0528337-A1 | New thiazolylbenzofuran derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206203-A1 | Administering leukotriene antagonist such as pranlukast | LTB4R2, LTB4R, LTC4S | CYP19A1 3938/4885RAB9A 3888/4885NPC1 1877/4885 |
| US-20170014384-A1 | METHOD FOR INHIBITING TUMOR METASTASIS | LTB4R, LTB4R2, LTA4H | CYP19A1 4090/4885RAB9A 3497/4885NPC1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.